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The betulinic acid derivative IC9564 is a potent anti-human immunodeficiency virus (anti-HIV) compound
that can inhibit both HIV primary isolates and laboratory-adapted strains. However, this compound did not
affect the replication of simian immunodeficiency virus and respiratory syncytial virus. Results from a syncy-
tium formation assay indicated that IC9564 blocked HIV type 1 (HIV-1) envelope-mediated membrane fusion.
Analysis of a chimeric virus derived from exchanging envelope regions between IC9564-sensitive and IC9564-
resistant viruses indicated that regions within gp120 and the N-terminal 25 amino acids (fusion domain) of
gp41 are key determinants for the drug sensitivity. By developing a drug-resistant mutant from the NL4-3
virus, two mutations were found within the gp120 region and one was found within the gp41 region. The
mutations are G237R and R252K in gp120 and R533A in the fusion domain of gp41. The mutations were
reintroduced into the NL4-3 envelope and analyzed for their role in IC9564 resistance. Both of the gp120
mutations contributed to the drug sensitivity. On the contrary, the gp41 mutation (R533A) did not appear to
affect the IC9564 sensitivity. These results suggest that HIV-1 gp120 plays a key role in the anti-HIV-1 activity
of IC9564.
Betulinic acid derivatives have been shown to inhibit human
immunodeficiency virus type 1 (HIV-1) replication (7, 15, 17,
20, 22, 28, 29, 32, 34, 40, 41, 43). Dependent upon chemical
structure, betulinic acid derivatives have been reported as in-
hibitors of HIV-1 entry (29, 40), HIV-1 protease (43) or re-
verse transcriptase (RT) (34). Triterpene derivatives, such as
RPR103611, are reported to block HIV-1-induced membrane
fusion (29, 40). Since a number of betulinic acid derivatives
have been shown to inhibit HIV-1 at a very early stage of the
virus life cycle, these compounds have the potential to become
useful additions to current anti-HIV therapy, which relies pri-
marily on combinations of RT and protease inhibitors.
HIV-1 entry involves both viral and cellular components.
HIV-1 envelope glycoproteins, gp120 and gp41, play a key role
in initiating HIV-1 infection. The early steps of HIV-1 entry
begin with the interaction between gp120 and cellular factors,
CD4 and the chemokine receptors (1, 8, 10, 11, 13, 14). This
interaction was proposed to trigger conformational changes in
the viral envelope glycoproteins (38), which allow HIV-1 gp41
to attack the cell membrane and progress to the late steps of
viral entry, including membrane mixing and fusion. While CD4
is important for the virus to bind to CD4 T lymphocytes,
chemokine receptors are also needed for successful HIV-1
entry. The two major chemokine receptors used by most HIV-1
isolates are CXCR4 and CCR5. Many HIV-1 primary isolates
from early stages of HIV-1 infection utilize CCR5 as a fusion
cofactor, while viruses isolated from late stages of infection
often use CXCR4 (30).
Many anti-HIV agents were found to block HIV-1 entry
through interfering with envelope and CD4 or chemokine re-
ceptor interaction. Based on their targets, the compounds
could interact with gp120, gp41, or chemokine receptors. For
example, a G quartet-forming oligonucleotide inhibits HIV
entry by binding to the V3 loop of gp120 (3). Reagents that
target gp41 were also demonstrated to be very potent against
HIV-1. Jiang et al. reported that a peptide derived from the
ectodomain of gp41 can interact with the fusion domain of
gp41 and inhibit HIV entry (21). Other gp41-derived peptides
such as DP178 could block HIV infection at nanomolar con-
centrations (42). In addition to gp120 and gp41, chemokine
receptors are targets of certain HIV entry inhibitors. The li-
gands of CCR5 (RANTES, MIP-1a, MIP-1b, and MCP-2) are
able to inhibit HIV-1 entry (9, 16). Likewise, the CXCR4
ligand SDF1a can effectively block HIV-1 infection (33). In
addition, chemokine receptor antagonists have been identified
as inhibitors of HIV-1 envelope-mediated membrane fusion.
Most of these inhibitors interfere with the interaction between
the HIV-1 envelope and CXCR4. For example, the bicyclam
AMD3100 (39), a synthetic peptide T22 (31), and a polypep-
tide ALX40-4C (12) are reported to inhibit HIV-1 entry by
targeting CXCR4. In contrast, vMIP-II and a distamycin ana-
log, NSC651016, were described as broad-spectrum chemokine
antagonists (18, 24).
Development of anti-HIV agents with a novel mode of action
is one of our ongoing efforts to improve current AIDS therapy
(7, 15, 17, 22, 28, 41). Betulinic acid derivatives are one of the
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chemical classes that have been identified to have potent anti-
HIV activity. One of the betulinic acid derivatives, IC9564
(4S-[8-(28 betuliniyl) aminooctanoylamino]-3R-hydroxy-6-
methylheptanoic acid), has been used for further pharmaco-
logical studies in our laboratory. This compound is a stereo-
isomer of the HIV-1 entry inhibitor RPR103611 (29, 40). The
molecular target for RPR103611 has been implicated by La-
brosse et al. as the HIV-1 transmembrane glycoprotein gp41
(26, 27).
In order to understand the pharmacological profile, we have
studied the anti-HIV activity and the mechanism of action of
IC9564. Effects of this compound on HIV-1 primary isolates as
well as laboratory-adapted strains were evaluated. In addition,
simian immunodeficiency virus (SIV) and respiratory syncytial
virus (RSV) were used to test the specificity of the antiviral
activity of IC9564. To study the role of gp41 and gp120 in the
drug sensitivity, a chimeric virus derived from IC9564-resistant
and -sensitive strains was used. Further analysis of the drug-
resistant variants was done to identify the amino acid residues
that were important for the drug sensitivity.
MATERIALS AND METHODS
Preparation of IC9564. Butoxycarbonyl (Boc)-L-leucine was methylated with
methyl chloroformate in the presence of dimethylaminopyridine and triethyl-
amine to give methyl ester (23), which was then reduced by diisobutylaluminum
hydride in anhydrous ether at 278°C to obtain leucinal as described in reference
44. Aldol reaction of the aldehyde with benzyl acetate at 278°C afforded a
mixture of 3R,4S and 3S,4S diastereomers (36). The Boc group of the optically
pure 3R,4S statine derivative was removed by trifluoroacetic acid in CH2Cl2 (2).
The resulting amine was readily coupled with Boc-8-aminooctanoic acid in the
presence of EDC [1-ethyl-3-(39-dimethylaminopropyl)-carbodiimide hydrochlo-
ride] to yield the amide intermediate 4S-(N-Boc-8-aminooctanoylamino-3R-hy-
droxy-6-methylheptanoic acid benzyl ester. Removing the Boc group of the
above amide, followed by conjugation with acid chloride of 3-acetyl betulinic
acid, produced the betulinic acid derivative IC9563. Finally, saponification of
benzyl acetyl ester IC9563 obtained the statine analog IC9564.
Chimeric virus. The IC9564-sensitive strain NL4-3 and the IC-resistant pri-
mary isolate strain DH012 were used to construct a chimeric virus, NL4-3/
DH012, that contained the entire gp120 sequence and the N-terminal 25 amino
acids (fusion domain) of gp41 from DH012 virus in the genetic background of the
NL4-3 virus. This was constructed by replacing the EcoRI/HgaI NL4-3 envelope
fragment with the EcoRI/HgaI DH012 envelope fragment. This EcoRI/HgaI
fragment contains the entire gp120 and N-terminal 25 amino acids of gp41.
Briefly, the DH012 EcoRI/HgaI fragment was used to ligate with the NL4-3
HgaI/BamHI fragment that spans the rest of the gp41 region. The resulting
chimeric EcoRI/BamHI envelope fragment was used to replace the same region
of the pNL4-3 plasmid that contains the entire NL4-3 viral genome.
Selection of IC9564-resistant viruses and cloning HIV-resistant envelope. The
NL4-3 virus was grown in increasing concentrations of IC9564. Initially, the virus
and CEM cells were cultured in the presence of 0.5 mg of IC9564 ml. The
virus-cell culture was passed every 3 days until a mass cytopathic effect was
observed (day 8). The IC9564 concentration was further escalated to 2 mg/ml and
5 mg/ml (selection cycles 2 and 3) to select the drug-resistant mutant. The culture
supernatants were collected at day 8 and day 9 for selection cycles 2 and 3,
respectively. The replication kinetics of the drug-resistant mutants are similar to
those of the wild-type NL4-3. The human chromosomal DNA containing the
drug-resistant virus genome was prepared by extracting chromosomal DNA from
the virus-infected CEM cells. The drug-resistant HIV-1 envelope sequence was
amplified using a PCR. The 59 primer used in the PCR was located in the
junction of the gp120 signal peptide and the N terminus of the gp120 sequence
(59-GATGATCTGTAGTGCTACAG-39). The 39 primer was located in the cy-
toplasmic domain of gp41 (59-CGTCCCAGATAAGTGCT-39). The 2.2-kb PCR
product was cloned into a TA vector pCR3.1 (Invitrogen, Carlsbad, Calif.) for
sequence analysis.
Mutagenesis. The wild-type NL4-3 envelope was cloned into pBluescript II KS
plasmid (Stratagene, La Jolla, Calif.) using two restriction enzyme sites, KpnI and
XhoI. A quick-exchange mutagenesis kit (Stratagene) was used to introduce
mutations into the envelope sequence by following the protocol provided by the
manufacturer. Once mutagenesis was completed and the mutated envelope se-
quence was determined, the mutated envelopes were subcloned into a eukaryotic
expression vector, pSRHS (provided by Eric Hunter, University of Alabama),
using the restriction enzyme sites KpnI and XhoI. Each plasmid was sequenced
for the correct mutations.
Cell lines. The human T-lymphoblastoid cell lines Molt-4, CEM, MT4, and
AA5 were maintained in RPMI 1640 medium containing 10% fetal bovine serum
and 100 U of penicillin and streptomycin per ml. The HIV-1 envelope glyco-
proteins were expressed on the surface of monkey kidney COS cells and grown
in Dulbecco’s modified Eagle medium containing 10% fetal bovine serum, and
100 U of penicillin and streptomycin per ml. Cell viability was assessed by trypan
blue exclusion. Cells were counted with a hemacytometer.
Cell fusion assay. Cell fusion assays were performed as previously described
(6). Molt-4 cells (7 3 104) were incubated with 104 HIV-1IIIB chronically infected
CEM cells (CEM-IIIB) in 96-well half-area flat-bottomed plates (Costar) in 100
ml of culture medium. Compounds were tested at various concentrations and
incubated with the cell mixtures at 37°C for 24 h. Multinucleated syncytia were
enumerated by microscopic examination of the entire contents of each well.
Alternatively, the CEM-IIIB cells were replaced with COS cells transfected with
the HIV envelope gene in the expression vector pSRHS. Electroporation was
performed to express the HIV-1 envelope on COS cells. A modified protocol
used for the electroporation was previously described (4). Briefly, COS cells
(106) in culture medium were incubated with 2 mg of pSRHS plasmid on ice for
10 min. The electroporation was performed using a gene pulser (Bio-Rad, Her-
cules, Calif.) with the capacitance set at 950 mF and the voltage set at 150 mA.
The transfected COS cells were cultured for 1 day prior to the fusion assay.
HIV-1 infectivity reduction assay. The cells used in the infectivity reduction
assay for NL4-3 were CEM lymphoblastoid cells. MT4 cells were used in the
assays that involve DH012 and the viruses containing DH012 envelopes. The
virus-cell culture supernatants were collected at day 7 and analyzed for viral
replication (RT activity) to determine the 90% inhibitory concentration (IC90) of
IC9564. Human peripheral blood mononuclear cells (PBMC) were used for the
infectivity reduction assay of the primary isolates 89.6, DH012, and QZ4734. The
culture supernatants collected at day 8 were used to determine the antiviral
activity of IC9564. The cell viability of IC9564-treated PBMC or CEM cells
without virus infection was checked at the end of the assays. No cytotoxicity was
detected at all the tested drug concentrations.
In detail, 20 ml of serially diluted virus stock (DH012 or NL4-3) was incubated
for 60 min at ambient temperature with 20 ml of the indicated concentration of
anti-HIV agents in RPMI 1640 containing 10% fetal bovine serum and antibi-
otics in a 96-well microtiter plate. Twenty microliters of MT4 or CEM cells at 6 3
105 cells/ml was added to each well. Cultures were incubated at 37°C in a
humidified CO2 incubator. Fresh medium (180 ml) was added to the cultures at
day 2. The cells were fed at day 4 by replacing 120 ml of cultural supernatant with
fresh medium. On day 7 postinfection, culture supernatants were harvested and
assayed for RT activity, as described previously (5, 6), to monitor viral replica-
tion. A PBMC-based infectivity reduction assay was used to evaluate the effect of
anti-HIV-1 agents on primary isolates. The source for PBMCs was from HIV-
1-negative human donors (buffy coats from interstate blood bank). The PBMCs
were fractionated on lymphocyte separation medium and frozen in fetal calf
serum containing 10% dimethyl sulfoxide. Cells were thawed, activated with a
combination of OKT3 and CD28 antibodies, and cultured in IL-2-containing
medium 2 days before the viral infectivity assay. A 96-well microtiter plate was
used to set up the assay. To achieve the infectivity reduction assay, multiple virus
dilutions that cover 0.05 to 100 50% tissue culture infective doses were used to
infect the cells (2 3 105 cells; 100 ml/well). The cells were fed with 100 ml of fresh
medium at day 4. Samples (culture supernatants) were collected at day 8 for a
micro-RT assay to estimate the degree of virus infection.
RESULTS
Our previous results indicate that betulinic acid derivatives
possess anti-HIV activity (7, 15, 17, 22, 28, 41). These betulinic
acid derivatives can inhibit HIV-1 envelope-mediated mem-
brane fusion at concentrations ranging from 10 to 40 mg/ml,
which is at least 1,000-fold higher than that required to inhibit
viral replication. Therefore, HIV-1-induced membrane fusion
does not appear to be the primary target of these compounds.
However, a betulinic acid derivative, IC9564 (Fig. 1), was very
potent against HIV-1 envelope-induced membrane fusion. The
concentration of IC9564 required to inhibit fusion is compa-
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rable to that required to inhibit HIV-1 replication. This com-
pound inhibited replication of both HIV-1 primary isolates and
laboratory-adapted strains. The virus NL4-3 is a laboratory-
adapted strain; DH012, 89.6, and QZ4734 are primary isolates.
DH012 and 89.6 are dualtropic viruses that can use both CCR5
and CXCR4. The coreceptor usage of the clinical isolate
QZ4734 is unknown. NL4-3 is one of the most sensitive HIV-1
strains tested so far. In the virus infectivity reduction assay, the
IC90 of IC9564 for NL4-3 is 0.22 6 0.05 mM. The IC90 for the
known HIV-1 RT inhibitor AZT against NL4-3 in the same
assay is 0.045 mM. The IC90s for DH012, QZ4734, and HIV-1
89.6 are .5, 2.65, and 1.84 mM, respectively.
To test the antifusion activity, IC9564 was tested in a Molt-
4/CEM-IIIB fusion assay system. The concentration of IC9564
required to completely inhibit syncytium formation was 0.33
mM. The antifusion activity of IC9564 was totally lost with
minor side chain modifications such as the compound IC9563
(Fig. 1).
IC9564 did not significantly affect SIV or RSV replication at
concentrations up to 30 mM (data not shown). IC9564 was
evaluated against SIVmac251 infection of CEM3174 cells.
The RSV assays were carried out by using HEp-2 cells in a
plaque assay. The lack of activity against both SIV and RSV
suggests that IC9564 specifically disrupts HIV-1 entry rather
than a nonspecific charge-charge interaction or hydrophobic
binding.
HIV-1 envelope glycoproteins gp41 and gp120 are the key
viral proteins that induce membrane fusion. Thus, the enve-
lope glycoproteins are likely involved in the antifusion activity
of IC9564. The results given above show that the primary
isolate DH012 was at least 20-fold more resistant to the com-
pound than HIV-1 NL4-3. Based on this observation, we have
used chimeric viruses derived from DH012 and NL4-3 to study
the role of gp41 and gp120 in drug sensitivity. The drug sen-
sitivity of a chimeric virus, NLDH120, is similar to that of
DH012 (Fig. 2). NLDH120 contains the entire gp120 sequence
and the N-terminal 25 amino acids (fusion domain) of gp41
from the DH012 virus in the genetic background of NL4-3. The
gp120/fusion domain sequence of NL4-3 was replaced with the
corresponding DH012 sequence using two restriction enzyme
sites, EcoRI and HgaI. Figure 2 shows the results of an HIV-1
infectivity reduction assay using HIV-1 RT activity as a marker
for HIV-1 replication. The results in Fig. 2 clearly indicate that
the gp120/fusion domain sequence from DH012 is sufficient to
convert NL4-3 into a drug-resistant virus.
There are many differences in the envelope sequences be-
tween DH012 and NL4-3, so comparison of the envelope se-
quence did not offer further insight into what could be the key
FIG. 1. Chemical structures of IC9563, IC9564, and RPR103611.
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determinants that are responsible for the drug sensitivity.
Therefore, a drug-resistant mutant derived from the IC9564
sensitive NL4-3 was used to further map the amino acid resi-
dues involved in the drug sensitivity. This was accomplished by
growing the virus in increasing concentrations of the com-
pound to develop a drug-resistant mutant. The virus that es-
caped the inhibitory activity of IC9564 at 5 mg/ml was clearly
more resistant to the compound (Fig. 3A and B).
The envelope of the drug-resistant mutant virus was se-
quenced (Fig. 3C) to determine the changes that had taken
place. The results indicate that there were two mutations
within the gp120 region and one within the gp41 region. The
first mutation in gp120 (M1) is an amino acid change from
glycine to arginine (G237R). The second mutation within
gp120 (M2) is a change from arginine to lysine (R252K). The
third mutation (M3), located within the gp41 fusion domain, is
an arginine-to-alanine change (R533A).
The contribution of each mutation to the resistant pheno-
type was evaluated through envelope-mediated fusion. Muta-
tions were introduced into the envelope sequence of NL4-3
and cloned into the KpnI/XhoI site of the eukaryotic expression
vector pSRHS. To determine if each mutation in the envelope
was sensitive or resistant to IC9564, a cell-cell fusion system
was used as a model to evaluate the effect of the drug on HIV-1
envelope-mediated membrane fusion. Figure 4A shows that
the G237R mutation has greater impact on the sensitivity to
IC9564 than the other two mutations. The IC50 of IC9564 for
the wild type envelope-induced membrane fusion was 0.02 mM.
The G237R mutation was sixfold less sensitive to IC9564, with
an IC50 at 0.12 mM. A 10-fold increase in resistance (IC50 at 0.2
mM) was observed when both of the gp120 mutations (M12)
were introduced into the envelope. To test whether the second
gp120 mutation alone can affect the drug sensitivity, an enve-
lope construct with the R252K mutation (M2) was tested in the
fusion assay. M2 is 1.6-fold less sensitive to IC9564 (data not
shown) than the wild-type NL4-3 envelope. Addition of the
third mutation (M123), located in the fusion domain of gp41,
did not significantly alter the drug sensitivity of M12. A known
fusion inhibitor, DP178, was used for comparison with IC9564
in the same experiment. Figure 4B shows that neither M1 nor
M12 is more resistant to DP178 than the wild type. The DP178
IC50s for M1, M12, and wild type are 0.0025, 0.0033, and
0.0055 mM, respectively. In contrast, addition of the third mu-
tation (M123) rendered the envelope slightly less sensitive to
DP178 (IC50, 0.018 mM). The R533A change is close to a
region where mutations have been identified from DP178-
resistant HIV-1 strains (37).
DISCUSSION
Our results indicate that IC9564 is a potent HIV-1 entry
inhibitor that can inhibit HIV replication at submicromolar
concentrations. Among the betulinic acid derivatives tested in
our laboratory, IC9564 is one of the most potent compounds
that can primarily block HIV-1 replication at the entry step. A
minor modification in chemical structure of IC9564 is sufficient
to change its mode of action. IC9563, being totally inactive
against membrane fusion, is chemically similar to IC9564.
HIV-1 can become resistant to IC9564 with changes in the
gp120 sequence.
A stereoisomer of IC9564, RPR103611, was reported to
inhibit HIV-1 by blocking viral entry. These two compounds
appear to be equally potent in their anti-HIV-1 activity and
antifusion activity. It is likely that the two compounds share a
mode of action. However, it is possible that changes in stereo-
specificity could result in different biological activities. Pre-
viously, we have reported a potent anti-HIV-1 coumarin de-
rivative, a camphanoyl khellacton (DCK), that can inhibit
FIG. 2. MT4 cells were used in the infectivity reduction assay. The chimeric virus NLDH120 contains the entire gp120 and N-terminal 25 amino
acids of the gp41 sequence of DH012 in the genetic background of NL4-3. Detection of HIV-1 RT activity is used as an indicator of HIV-1
replication in the MT4 cells.
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HIV-1 at subnanomolar concentrations. A stereoisomer of
DCK is essentially inactive against HIV-1 (19).
The cysteine loop region of gp41 was reported to be the
envelope determinant that is important for the antiviral activity
of RPR103611 (26). Sequence analysis of RPR103611-resis-
tant mutants indicated that a single amino acid change, I84S, in
HIV-1 gp41 is sufficient to confer the drug resistance. The
position 84 corresponds to the isoleucine at position 595 of the
numbering system used in this study. However, this I84S mu-
tation has not occurred in some of the naturally RPR103611-
resistant HIV-1 strains, such as NDK or ELI (26). This dis-
crepancy has led Labrosse et al. to reexamine the viral
determinants that are responsible for the inhibitory activity of
RPR103611. Their recent report indicates that the antiviral
efficacy of RPR103611 depends on the stability of gp120-gp41
complexes (27). It is possible that the I84S (I595S) mutation
observed in the RPR103611 escape mutant creates a confor-
mational change that affects the structure and function of
HIV-1 envelope glycoproteins. Indeed, it has been reported
that an escape mutant resistant to a gp120-specific neutralizing
monoclonal antibody was associated with a single amino acid
mutation in gp41 (35). Therefore, it is not totally impossible
that gp120 plays a certain role in the drug sensitivity to
RPR103611.
In the case of the IC9564-resistant chimeric virus NLDH120,
there is no change in the isoleucine at position 595 that rep-
resents the wild-type NL4-3 sequence. The region that confers
the drug resistance in this chimeric virus is derived from the
entire DH012 gp120 region and a fusion domain of DH012
gp41 that spans the first 25 amino acids of gp41. Furthermore,
the key mutations in the envelope of the IC9564-resistant
NL4-3 mutant are G237R and R252K in gp120. There is no
I84S (I595S) mutation in this drug-resistant mutant. Both of
the amino acid changes are located in the inner domain of the
HIV-1 gp120 core. The inner domain of the gp120 core is
believed to interact with gp41 (25). The two gp120 mutations
FIG. 3. Autoradiograph of HIV-1 infectivity reduction assay.
HIV-1 RT activity of the wild-type NL4-3 (A) and drug-resistant mu-
tant (B) virus was used as an indicator of HIV-1 replication in CEM
cells. Growing the NL4-3 virus in increasing concentrations of IC9564
developed the drug-resistant mutant. (C) The envelope of the mutant
virus was sequenced. The amino acid changes in the envelope se-
quence of the drug-resistant mutants are indicated as shown. The
amino acid positions are numbered as in reference 25, where residue
1 of gp120 is the methionine at the N terminus of the gp120 signal
peptide.
FIG. 4. Effects of IC9564 and DP178 on envelope-mediated fusion.
Various concentrations of IC9564 (A) or DP178 (B) were added to the
fusion assay (COS-env/Molt-4) with different envelope mutants. Each
data point represents the average of a quadrupled experiment. The
data values shown are means 6 standard deviations (error bars). For
example, an average of 81 syncytia were observed in the absence of
IC9564 for the NL4-3 envelope-mediated membrane fusion. The wild-
type envelope was derived from the NL4-3 virus, and the mutants’
envelopes were constructed in pSRHS by mutagenesis, as described in
Materials and Methods. M1 is the NL4-3 envelope with a G237R
mutation; M12 is the envelope with two gp120 mutations, G237R and
R252K. M123 possesses all the three mutations, G237R, R252K, and
R533A, of the drug-resistant mutant.
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are not located in the regions that are well characterized for
CD4 binding or interactions with chemokine receptors. There-
fore, how the mutations affect the structure and function of the
envelope glycoprotein and chemokine receptor usage remains
unclear.
An anti-HIV agent that can block the early stages of the
virus life cycle might have potential to be very useful in anti-
HIV therapy. The drugs that are currently used in combination
drug therapy are either HIV-1 RT or protease inhibitors. Al-
though the use of highly active antiretroviral therapy can suc-
cessfully control HIV-1 viremia in many cases, latent infection
and side effects of the drugs often compromise the effective-
ness of the therapy. Drugs with different modes of action such
as IC9564 have the potential to add to the repertoire of anti-
HIV therapy. Some HIV-1 primary isolates, such as DH012,
are relatively less sensitive to IC9564. Synthesis of IC9564
analogs with better potency against these naturally occurring
resistant HIV-1 strains would enhance the potential clinical
usefulness for this class of HIV-1 entry inhibitors.
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